<DOC>
	<DOCNO>NCT00407121</DOCNO>
	<brief_summary>Intravitreal injection Bevacizumab patient Neovascular Membranes secondary intraocular inflammation . We inject single injection Bevacizumab ( 2.5 mg/0.1 ml ) evaluate visual acuity , Fluorescein angiogram retinal thickness Optical Coherence Tomography ( OCT ) 4 patient Vogt Koyanagi Harada disease , 1 patient Serpiginous Choroidopathy 1 patient Multifocal Choroiditis .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Inflammatory Neovascular Membranes</brief_title>
	<detailed_description />
	<mesh_term>Choroiditis</mesh_term>
	<mesh_term>Uveomeningoencephalitic Syndrome</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Clinical Diagnose Patient Consent Chronic stage inflammation eye age low 30 yo . Systemic condition</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Neovascular Membrane</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>